07:00 , Jul 16, 2001 |  BC Week In Review  |  Company News

BioFocus, Australian Cancer Technologies deal

BIO and Australian Cancer will develop small molecule tyrosine kinase receptor modulators for use in treating breast cancer. BIO will contribute its Retroviral Display assay system to detect cell surface receptor modulator compounds and Australian...
07:00 , Jul 11, 2001 |  BC Extra  |  Company News

BioFocus, Australian Cancer in oncology deal

BioFocus (LSE:BIO) and Australian Cancer Technologies (Sydney, Australia) will develop small molecule tyrosine kinase receptor modulators for use in treating breast cancer. BIO will contribute its Retroviral Display assay system to detect cell surface receptor...
07:00 , Jun 18, 2001 |  BioCentury  |  Strategy

Creating business systems

Creating business systems How some chemistry companies are diversifying. AMRI, ARQL and PCOP (stripes) reported profts last year. EVT (bars) is aiming to be profitable in 2002. On May 23, BIO announced it will acquire...
07:00 , Jun 18, 2001 |  BioCentury  |  Strategy

Reinventing chemistry

When combinatorial chemistry was first developed in the late 1980s, it represented a paradigm shift that totally changed the way chemistry was done. Yet the first generation of chemistry companies failed to build sustainable businesses...
07:00 , May 29, 2001 |  BC Week In Review  |  Company News

BioFocus, Cambridge Drug Discovery Ltd., Millennium, Teijin Ltd. deal

BIO will acquire Cambridge Drug, a biology services company, for £27.5 million ($39.5 million) in stock. Cambridge Drug focuses on assay and high throughput screening systems to discover small molecules that modify cellular signaling and...
07:00 , May 29, 2001 |  BioCentury  |  Finance

France rising

French biotech is bucking the chilled markets. Indeed, counting this week's announcement of a E 35 million ($30.8 million) pre-IPO financing by neurological play Neurotech, five French biotech deals account for 26% of European company...
07:00 , May 23, 2001 |  BC Extra  |  Top Story

BioFocus to acquire Cambridge Drug

AIM-listed BioFocus (LSE:BIO) will acquire Cambridge Drug Discovery (Cambridge, U.K.), a biology services company, for 27.5 million ($39.5 million) in stock. Cambridge Drug focuses on assay and high throughput screening systems for the discovery of...
08:00 , Jan 11, 2001 |  BC Extra  |  Financial News

Cambridge Drug Discovery raises 7.5 million

Cambridge Drug ( Cambridge , U.K.) said it raised 7.5 million ($11.3 million) in a private financing. Funds will be used to finance a new chemistry capability, along with the company's ion channel and kinase...
07:00 , Jul 31, 2000 |  BC Week In Review  |  Company News

Ardana Bioscience board of directors update

Ardana Bioscience , Edinburgh, U.K.   Business: Reproductive   Appointed: Ian Kent, chairman of AdPro Tech Ltd. and Cambridge Drug Discovery Ltd., as chairman  ...
07:00 , Apr 24, 2000 |  BC Week In Review  |  Company News

Cambridge Drug Discovery Ltd., Teijin Ltd. deal

Teijin will use Cambridge Drug's target and assay development technology, high throughput screening and compound library to find lead compounds to treat metabolic disorders. Teijin will pay research fees and milestones. Cambridge Drug Discovery Ltd....